Abstract
Drug transport in the body is a necessary step, from dosage form administration to the pharmacological target of the drug substance. Absorption (A), distribution (D), metabolism (M) and Excretion (E), i.e. ADME properties of drug substances, all include elements of drug transport. Cell culture and tissue-based models are often used to predict drug ADME properties, and to gain mechanistic insight into these. In the present chapter, the kinetics of drug transport and transport via drug transporters is described. The most common cell culture model for studying intestinal transport, i.e. the Caco-2 cell model is described in detail, and protocols for culturing and studying Caco-2 cells are included as an Appendix. Drug transport via carriers and transporters are important for drug substance ADME properties, and proton-coupled drug transport via the amino acid and peptide transporters PAT1 and PEPT1 in Caco-2 cells are discussed. Renal and hepatic models are also mentioned, as well as in vitro models of the blood brain barrier, which are discussed in more details. Even though in vitro models are easy to use and provide relatively reproducible results, areas of concerns and potential pitfalls are highlighted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbott J (2014) In vitro models of CNS barriers. In: Hammarlund-Udenaes M (ed) Drug delivery to the brain: Physiological concepts, methodologies and approaches. Springer, New York
Amtorp O (1980) Estimation of capillary-permeability of inulin, sucrose and mannitol in rat-brain cortex. Acta Physiol Scand 110:337–342
Anderberg EK, Nystrom C, Artursson P (1992) Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J Pharm Sci 81:879–887
Antherieu S, Chesne C, Li R, Guguen-Guillouzo C, Guillouzo A (2012) Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol In Vitro 26:1278–1285
Antunes F, Andrade F, Araujo F, Ferreira D, Sarmento B (2013) Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 83:427–435
Araujo F, Sarmento B (2013) Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies. Int J Pharm 458:128–134
Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880–885
Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27–43
Audus KL, Bartel RL, Hidalgo IJ, Borchardt RT (1990) The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm Res 7:435–451
Ballet S, Betti C, Novoa A, Tömböly C, Nielsen CU, Helms HC, Lesniak A, Kleczkowska P, Chung N, Lipkowski A, Bordin B, Tourwé D, Schiller P (2014) In vitro membrane permeation studies and in vivo antinociception of glycosylated Dmt1-DALDA analogues. ACS Med Chem Lett 5(4):352–357. doi:10.1021/ml4004765
Bowman PD, Ennis SR, Rarey KE, Betz AL, Goldstein GW (1983) Brain microvessel endothelial-cells in tissue-culture—A model for study of blood-brain-barrier permeability. Ann Neurol 14:396–402
Bravo SA, Nielsen CU, Amstrup J, Frokjaer S, Brodin B (2004a) In-depth evaluation of Gly-Sar transport parameters as a function of culture time in the Caco-2 cell model. Eur J Pharm Sci 21:77–86
Bravo SA, Nielsen CU, Amstrup J, Frokjaer S, Brodin B (2004b) Epidermal growth factor decreases PEPT2 transport capacity and expression in the rat kidney proximal tubule cell line SKPT0193 cl.2. Am J Physiol Renal Physiol 286:F385–F393
Bravo SA, Nielsen CU, Frokjaer S, Brodin B (2005) Characterization of rPEPT2-mediated Gly-Sar transport parameters in the rat kidney proximal tubule cell line SKPT-0193 cl.2 cultured in basic growth media. Mol Pharm 2:98–108
Brayden DJ, Bzik VA, Lewis AL, Illum L (2012) CriticalSorb promotes permeation of flux markers across isolated rat intestinal mucosae and Caco-2 monolayers. Pharm Res 29:2543–2554
Bretschneider B, Brandsch M, Neubert R (1999) Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 16:55–61
Chen Z, Fei YJ, Anderson CM, Wake KA, Miyauchi S, Huang W, Thwaites DT, Ganapathy V (2003) Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. J Physiol 546:349–361
Cohen-Kashi-Malina K, Cooper I, Teichberg VI (2012) Mechanisms of glutamate efflux at the blood-brain barrier: Involvement of glial cells. J Cereb Blood Flow Metab 32:177–189
Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P (2006) Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci 27:354–362
Crone C, Olesen SP (1982) Electrical-resistance of brain micro-vascular endothelium. Brain Res 241:49–55
Dehouck MP, Meresse S, Delorme P, Fruchart JC, Cecchelli R (1990) An easier, reproducible, and mass-production method to study the blood-brain-barrier invitro. J Neurochem 54:1798–1801
Deli MA, Abraham CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol Neurobiol 25:59–127
Delie F, Rubas W (1997) A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: Advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 14:221–286
Eisenblatter T, Huwel S, Galla HJ (2003) Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 971:221–231
Fischer SM, Brandl M, Fricker G (2011) Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. Eur J Pharm Biopharm 79:416–422
Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221–226
Franke H, Galla HJ, Beuckmann CT (1999) An improved low-permeability in vitro-model of the blood-brain barrier: Transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res 818:65–71
Franke H, Galla HJ, Beuckmann CT (2000) Primary cultures of brain microvessel endothelial cells: A valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Protoc 5:248–256
Frolund S, Marquez OC, Larsen M, Brodin B, Nielsen CU (2010) Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol 159:1339–1353
Frolund S, Rapin N, Nielsen CU (2011) Gaboxadol has affinity for the proton-coupled amino acid transporter 1, SLC36A1 (hPAT1)—A modelling approach to determine IC(50) values of the three ionic species of gaboxadol. Eur J Pharm Sci 42:192–198
Frolund S, Langthaler L, Kall MA, Holm R, Nielsen CU (2012) Intestinal drug transport via the proton-coupled amino acid transporter PAT1 (SLC36A1) is inhibited by Gly-X(aa) dipeptides. Mol Pharm 9:2761–2769
Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD (2001) Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci 12:215–222
Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Oberg JO, Osterberg T (2005) In vitro models for the blood-brain barrier. Toxicol in Vitro 19:299–334
Gripon P, Rumin S, Urban S, Le SJ, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655–15660
Gumbleton M, Audus KL (2001) Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 90:1681–1698
Hakkarainen JJ, Pajander J, Laitinen R, Suhonen M, Forsberg MM (2012) Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells. Int J Pharm 436:426–443
Hellinger E, Veszelka S, Toth AE, Walter F, Kittel A, Bakk ML, Tihanyi K, Hada V, Nakagawa S, Thuy DHD, Niwa M, Deli MA, Vastag M (2012) Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 82:340–351
Helms HC, Brodin B (2014) Generation of primary cultures of bovine endothelial cells and setup of cocultures with rat astrocytes. In: Milner R (ed) Cerebral angiogenesis: Methods and protocols. Humana Press, New York
Helms HC, Waagepetersen HS, Nielsen CU, Brodin B (2010) Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth. AAPS J 12:759–770
Helms HC, Madelung R, Waagepetersen HS, Nielsen CU, Brodin B (2012) In vitro evidence for the brain glutamate efflux hypothesis: Brain endothelial cells cocultured with astrocytes display a polarized brain-to-blood transport of glutamate. Glia 60:882–893
Helms HC, Hersom M, Kühlmaa L, Badolo L, Nielsen CU, Brodin B (2014) An electrically tight blood-brain barrier model displays net brain-to-blood efflux of the P-gp substrate digoxin and the BCRP substrate estrone-3-sulfate. AAPS J 16(5):1046–1055. doi: 10.1208/s12248-014-9628-1. Epub 2014 Jun 17
Hidalgo IJ, Raub TJ, Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736–749
Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89:63–75
Hoheisel D, Nitz T, Franke H, Wegener J, Hakvoort A, Tilling T, Galla HJ (1998) Hydrocortisone reinforces the blood-brain barrier properties in a serum free cell culture system. Biochem Biophys Res Commun 244:312–316
Jung SJ, Choi SO, Um SY, Kim JI, Choo HY, Choi SY, Chung SY (2006) Prediction of the permeability of drugs through study on quantitative structure-permeability relationship. J Pharm Biomed Anal 41:469–475
Koljonen M, Hakala KS, Ahtola-Satila T, Laitinen L, Kostiainen R, Kotiaho T, Kaukonen AM, Hirvonen J (2006) Evaluation of cocktail approach to standardise Caco-2 permeability experiments. Eur J Pharm Biopharm 64:379–387
Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G (2014) In vitro-in vivo extrapolation method to predict human renal clearance of drugs. J Pharm Sci 103:994–1001
Laitinen L, Kangas H, Kaukonen AM, Hakala K, Kotiaho T, Kostiainen R, Hirvonen J (2003) N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharm Res 20:187–197
Larsen M, Larsen BB, Frolund B, Nielsen CU (2008) Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: Characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci 35:86–95
Larsen M, Holm R, Jensen KG, Brodin B, Nielsen CU (2009) Intestinal gaboxadol absorption via PAT1(SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol 157:1380–1389
Le VM, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109–117
Lemmen J, Tozakidis IEP, Bele P, Galla HJ (2013a) Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood-brain barrier after CITCO activation. Brain Res 1501:68–80
Lemmen J, Tozakidis IEP, Galla HJ (2013b) Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res 1491:1–13
Lennernas H (1997) Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 49:627–638
Lentz KA, Hayashi J, Lucisano LJ, Polli JE (2000) Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 200:41–51
Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, Hidalgo IJ (2011) Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39:1196–1202
Liang E, Chessic K, Yazdanian M (2000) Evaluation of an accelerated Caco-2 cell permeability model. J Pharm Sci 89:336–345
Lindahl A, Sjoberg A, Bredberg U, Toreson H, Ungell AL, Lennernas H (2004) Regional intestinal absorption and biliary excretion of fluvastatin in the rat: Possible involvement of mrp2. Mol Pharm 1:347–356
Matysiak-Budnik T, Heyman M, Candalh C, Lethuaire D, Megraud F (2002) In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: Effect of Helicobacter pylori. J Antimicrob Chemother 50:865–872
Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, Tanaka K, Niwa M (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54:253–263
Nielsen CU, Amstrup J, Steffansen B, Frokjaer S, Brodin B (2001a) Epidermal growth factor (EGF) inhibits glycylsarcosine (Gly-Sar) transport and hPepT1 expression in a human intestinal cell line. Am J Physiol Gastrointest Liver Physiol 281:G191–G199
Nielsen CU, Andersen R, Brodin B, Frokjaer S, Taub ME, Steffansen B (2001b) Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity to and transport via hPepT1 in the human intestinal Caco-2 cell line. J Controlled Release 76:129–138
Nielsen CU, Carstensen M, Brodin B (2012) Carrier-mediated gamma-aminobutyric acid transport across the basolateral membrane of human intestinal Caco-2 cell monolayers. Eur J Pharm Biopharm 81:458–462
Nohr MK, Hansen SH, Brodin B, Holm R, Nielsen CU (2014) The absorptive flux of the anti-epileptic drug substance vigabatrin is carrier-mediated across Caco-2 cell monolayers. Eur J Pharm Sci 51:1–10
Ocheltree SM, Shen H, Hu Y, Xiang J, Keep RF, Smith DE (2004) Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: Studies in wild-type and null mice. Pharm Res 21:1680–1685
Pardridge WM (2007) Drug targeting to the brain. Pharm Res 24:1733–1744
Patabendige A, Skinner RA, Abbott NJ (2013) Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance. Brain Res 1521:1–15
Perriere N, Demeuse PH, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud PO, Deli MA, Roux F (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 93:279–289
Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, Nguyen TH, Mrsny RJ (1996) Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 85:165–169
Shen H, Keep RF, Hu Y, Smith DE (2005) PEPT2 (Slc15a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus. J Pharmacol Exp Ther 315:1101–1108
Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209–1216
Smetanova L, Stetinova V, Kholova D, Kvetina J, Smetana J, Svoboda Z (2009) Caco-2 cells and Biopharmaceutics Classification System (BCS) for prediction of transepithelial transport of xenobiotics (model drug: caffeine). Neuro Endocrinol Lett 30(Suppl 1):101–105
Smith DE, Pavlova A, Berger UV, Hediger MA, Yang T, Huang YG, Schnermann JB (1998) Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm Res 15:1244–1249
Sondergaard HB, Bravo SA, Nielsen CU, Frokjaer S, Brodin B (2008) Cloning of the pig PEPT2 (pPEPT2) and characterization of the effects of epidermal growth factor (EGF) on pPEPT2-mediated peptide uptake in the renal porcine cell line LLC-PK1. Eur J Pharm Sci 33(4–5):332–342. doi: 10.1016/j.ejps.2008.01.001. Epub 2008 Jan 6
Sun H, Chow EC, Liu S, Du Y, Pang KS (2008) The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin Drug Metab Toxicol 4:395–411
Thomsen AE, Friedrichsen GM, Sorensen AH, Andersen R, Nielsen CU, Brodin B, Begtrup M, Frokjaer S, Steffansen B (2003) Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. J Controlled Release 86:279–292
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2000) Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. http://www.fda.gov/cder/guidance/index.htm
Vabeno J, Lejon T, Nielsen CU, Steffansen B, Chen WQ, Hui OY, Borchardt RT, Luthman K (2004a) Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: Synthesis and biological investigations. J Med Chem 47:1060–1069
Vabeno J, Nielsen CU, Ingebrigtsen T, Lejon T, Steffansen B, Luthman K (2004b) Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: Design, synthesis, stability, and biological investigations. J Med Chem 47:4755–4765
Veszelka ÁKMADS (2011) Tools of modelling blood-brain barrier penetrability. In: Tihanyi K, Vastag M (eds) Solubility, delivery and ADME problems of drugs and drug-candidates. Bentham Science, Washington, pp 166–188
Volpe DA (2008) Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci 97:712–725
Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL (1996) HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 85:1070–1076
Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp 71:113–128
Yang K, Köck K, Brouwer KLR (2013) Analysis of hepatic transport proteins. In: Sugiyama Y, Steffansen B (eds) Transporters in drug development. Springer-Verlag, New York, pp 201–223
Acknowledgement
The cell culture facility at the Department of Pharmacy (Maria Diana Læssøe Pedersen) is acknowledged for providing information for the appended Caco-2 cell protocol.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix: Culture and Application of Caco-2 Cells
Appendix: Culture and Application of Caco-2 Cells
Caco-2 cells from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ no.: ACC 169. the cells are proliferated and then frozen and kept in storage as stocks in a cryotank.
These Caco-2 cells have been shown to be optimal for use in 17–20 passages after a new thawing. Characterization studies of membrane transporters show that the cells can be used immediately after thawing.
After a new thawing, it takes about a week of culture before the cells are ready for the first trypsinization when two cell vials of cryopreserved cells are cultured in a T75 flask.
1.1 Microscopy
All flasks are controlled by light microscopy prior to every trypsinization or change of medium. This is to monitor the growth of the cells and to adjust condition.
1.2 Preparation of Growth Medium
1.2.1 Composition
DMEM ⊕: | |
Penicillin/streptomycin 10,000 U/mL/10 mg/mL (Pen/Strep) | 5.0 mL |
l-Glutamine (dissolve precipitate by gentle shaking) (l-Glu) | 5.0 mL |
Non-Essential Amino Acids (NEAA) | 5.0 mL |
DMEM ad. | 500 mL |
DMEM ⊕ + 10 % FBS: | |
Foetal bovine serum (FBS) | 50 mL |
DMEM⊕ ad. | 450 mL |
1.2.2 Aseptic Preparation of the Medium
Thaw FBS, pen/strep and l-Glu in a water bath at 37 °C and shake gently before use. Heat NEAA in a water bath to 37 °C.
Add 5 mL Pen/Strep, 5 mL NEAA and 5 mL l-Glu to a bottle of 500 mL DMEM.
This solution is referred to as DMEM ⊕.
Transfer 50 mL FBS to a sterile 500 mL bottle or to the bottle containing excess DMEM ⊕ from the previous medium preparation, then fill up with DMEM ⊕ to a final volume off 500 mL (termed DMEM ⊕ + 10 % FBS)
1.3 Trypsinization Procedure (Sub-cultivation)
This is normally carried out at a confluence of approx. 90 %.
Instructions for trypsinization of a 75/175 cm2 culture flask (T75/T175 flasks):
The cell culture should be handled aseptically in a LAF-bench.
-
1.
Pre-warm the DMEM ⊕ + 10 % FBS, PBS and Trypsin-EDTA in the 37 °C water bath (approx. 15 min). Trypsin-EDTA × 3 may be used.
-
2.
Control the culture flask visually and subject it to microscopy in order to check the cell layer for normal growth.
-
3.
Remove the culture medium with a Pasteur pipette without touching the cell layer. Rinse the culture with 10/30 mL 37 °C pre-warmed PBS by gently moving the flask back and forth. Then remove the PBS with a Pasteur pipette.
-
4.
Shake the trypsin-EDTA solution gently before use. Measure out 1 mL/T75 and 3 mL/T175 (0.5 mL/T25) and add this to the culture flasks by pouring it down the sides of the bottle. After this is done, move the flask so as to distribute the trypsin over the entire culture.
-
5.
Leave the culture flask in the incubator for approx. 10 min.
-
6.
By holding the flask perpendicular you will be able to see whether the cells have loosened, i.e. whether the trypsinization has lasted long enough. You can also check this by microscopy.
-
7.
Trypsinization is stopped by pouring 10/20–30 mL DMEM ⊕ + 10 % FBS over the loosened cells on the bottom of the flask (Serum inactivates the trypsin-EDTA).
-
8.
Aspirate the medium approx. 4–6 times with the pipette to separate any cell clumps (they can be a little difficult to separate in single-cell suspension. Further aspiration may be necessary for separation of cell clusters).
-
9.
The cell concentration is determined by transferring a small aliqot (9 μL) of the cell suspension to a MultiCount 10 disposable counting slide using a Pasteur pipette. It may be necessary to dilute the cell suspension further, if the cell concentration is too great (an optimum count figure is approx. 100 cells/9 fields). Perform the counting using a conventional light microscope. Count at least 2 × 9 fields (3 × 3 fields—magnification X 10, see SOP No. 269-B). The different counts must be approximately equal.
-
10.
The cell density in the suspension is calculated as follows:
Average number of cells/9 fields * 10,000 = number of cells/mL.
-
11.
A new passage is established by diluting the suspension to the desired concentration.
1.4 Seeding
Make sure the cells are evenly suspended in the pipette
1.4.1 Seeding in T-75 and T175 Flasks
The number of cells needed for seeding is dependent on passage No. Cell division is slower at the lower passage numbers. Therefore it is a good idea to seed a few more cells in the flasks when carrying out trypsinization during the first weeks after thawing.
Normally, the numbers of cells shown below are seeded, but with older passages it makes good sense to reduce the number of cells/flask a little:
Seed: | ||
T-75 | 2.6 × 105 cells/T75 | +13 mL DMEM ⊕ +10 % FBS |
T-175 | 6 × 106 cells/T175 | +33 mL DMEM ⊕ + 10 % FBS |
Change medium every second day and trypsinize the flask again 1 week later.
Calculation:
1.4.2 Seeding on Filters
Most often T12-transwells of polycarbonate from Costar are used (T12-cci3401). These filters have a pore size of 0.4 μm, a growth area of 1.12 cm2 and a diameter of 12 mm.
Various types of filters exist (see www.corning.com/lifesciences).
1.4.3 12-Well Filters (T12)
Prepare a cell suspension of 2.0 × 105 cells/mL. Of this, 0.5 mL is added apically, and 1.0 mL DMEM ⊕ + 10 % FBS is added basolaterally.
(Use 12 × 0.5 = 6 mL cell suspension. Prepare a total of 7 mL with 1.4 × 106 cells for 12 wells, corresponding to 1.0 × 105 cells /filter or 8.93 × 104 cells/cm2).
Calculation:
Cells seeded on filters are normally used for experiments on days 11–25, the cells must always be used for experiments the day after they have had their medium changed.
1.4.4 Seeding in Trays
1.4.5 12-Well Tray (B12)
Prepare a cell suspension of 2.26 × 105 cells/mL. Add 1.5 mL of this per well.
(Use 12 × 1.5 = 18 mL of cell suspension. Prepare a total of 20 mL with 4.52 × 106 cells for 12 wells, corresponding to 3.39 × 105 cells/well or 8.93 × 104 cells/cm2).
Calculation:
Cells must always be used for experiments the day after they have had their medium changed.
1.5 Change of Medium
1.5.1 T75/T175 Flasks
Remove the medium with a Pasteur pipette connected to a tube with vacuum suction.
After this, replace the medium with 13/33 mL DMEM ⊕ + 10 % FBS
1.5.2 6 and 12-Well Filters
-
Remove the medium with a Pasteur pipette connected to a tube with vacuum suction.
-
Empty the wells of medium, first basolaterally and then apically. This must be done without touching the cell layer on the filter (Avoid leaving the cells without medium for too long).
-
Then replace the medium with fresh DMEM ⊕ + 10 % FBS, first apically and then basolaterally with:
6-well filters:
apically:
2.0 mL
basolaterally:
2.5 mL
12-well filters:
apically:
0.5 mL
basolaterally:
1.0 mL
1.5.3 6, 12, 24 and 96-Well Trays
Cells are seeded in the wells once a week. After this, the medium must be changed every other day until the cells are to be used.
-
Remove the medium with a Pasteur pipette connected to a tube with vacuum suction. This must be done without touching the cell layer on the bottom.
(Avoid leaving the cells without medium for too long)
-
After this, replace the medium with fresh DMEM ⊕ + 10 % FBS with:
6-well:
3.0 mL
12-well:
1.5 mL
24-well:
1.0 mL
96-well:
0.2 mL
1.6 Freezing Procedure
The freezing of cells is done in an ordinary freshly prepared growth medium DMEM ⊕ with 15 % FBS, 5 % DMSO added, where the cell concentration is 2 × 106 cells/mL, corresponding to a cryotube.
In order to protect the cells during freezing, all work done in the period during which the cells are affected by DMSO must be carried out as quickly as possible. The same applies during the thawing procedure.
Preparation of medium for freezing:
1. | 90 % DMEM ⊕ + 10 % DMSO | (9 mL DMEM ⊕ + 1 mL DMSO) |
2. | 70 % DMEM ⊕ + 30 % FBS | (7 mL DMEM ⊕ + 3 mL FBS) |
NOTE: DMEM ⊕ + DMSO must be prepared aseptically and sterile-filtered before use.
1.6.1 Final Concentration in Freezing Medium
DMEM ⊕ | 80 % |
DMSO | 5 % |
FBS | 15 % |
Cells | 2 × 106 cells/mL |
1.7 Work Procedure
Normally four (or more) extra T175 flasks are seeded the week before in connection with the trypsinization.
-
1.
The trypsinization procedure is as usual.
The total number of cells is calculated.
-
2.
Then calculate how many cryotubes can be frozen (2 × 106 cells/tube).
-
3.
Put the cells in 15 mL centrifugal tubes with conical bottoms (max. 10 mL cell suspension/tube). Each tube can contain, for instance, 8 × 106 cells, corresponding to four cryotubes.
(There has to be at least 1 mL medium in which the cells can be resuspended after they have been centrifuged. This means that there must be enough cells for at least two cryotubes/centrifugal tubes)
Calculation:
$$ Number\ of\ mL\ \left( cell\ susp.\right)=\frac{8\times {10}^6\ \left(\frac{cells}{mL}\right)}{conc.\ of\ cell\ susp.\ \left(\frac{cells}{mL}\right)} $$The tubes must all contain the same amount of medium. If there are an odd number of tubes, prepare an extra tube containing an equal amount of water. Place the tubes in pairs opposite one another in the centrifuge.
-
4.
Centrifuge the cells at approx. 1000 g for 10 min −4 °C.
-
5.
When preparing cryotubes, mark them with:
Cell type
Date
Passage No.
Cell concentration
Your initials
(Increase the passage No. by 1 in connection with the trypsinization, so that the new passage no. is noted on the cryotube. On thawing, note the new passage no. on the T75 flask.)
-
6.
Carefully remove the supernatant from the centrifugal tube using suction.
-
7.
Carefully resuspend the cells in 1 mL, corresponding to two cryotubes, DMEM ⊕ + 30 % FBS per tube (mL DMEM ⊕ + 30 % FBS depends on how many cells are in the centrifugal tube)
-
8.
Transfer the cell suspension to two cryotubes (with a silicon gasket), each containing 0.5 mL.
-
9.
Carefully add 0.5 mL DMEM ⊕ + 10 % DMSO drop wise to each cryotube.
The cryotubes are placed in a special freezing box, Nalgene® Cryo 1 °C Freezing Container (which is usually located in the refrigerator outside the cell room). The freezing box can hold a maximum of 18 cryotubes per freezing. Alternatively, a specially-made polystyrene box can be used for the freezing.
The freezing box/polystyrene box is so adjusted that freezing takes place at a rate of 1 degree/min.
Place the freezing box/polystyrene box in the −80 °C freezer for a minimum of 2 h.
-
10.
After freezing at −80 °C for at least 2 h, the cryotubes are moved to one of the cryotanks.
This is done either by placing 4–5 cryotubes in a cane (a holder specially made for cryotubes), which is then placed in the appropriate section of the cryotank (small/medium)
The cryotank is divided into several sections, which can each contain a certain number of canes. Number all canes in a section consecutively, and write these numbers with a marker pen on the broad end. Each cane can hold a maximum of six cryotubes.
Each cell line has a special section in the cryotank, which can be seen in the freezing folder.
Or transfer the cryotubes to a special freezing box (which holds 96 tubes) and place in one of the holders in the large cryotank.
-
11.
The freezing tables must be filled in with all the relevant information in the folder for the cell stock.
All work with cells from item 7 to 10 must be carried out as quickly as possible to avoid the cells being damaged during freezing and the transferal to the cryotank .
1.8 Thawing Procedure
When thawing new cells received from the DSMZ, follow the thawing procedure found in the “product information sheet” that comes with them.
With other thawing, follow the thawing procedure below.
1.8.1 Work Procedure
-
1.
Add 13 mL of DMEM ⊕ + 10 % FBS to a T75 flask and place it in the incubator for approx. 15 min (a T25 with 5 mL DMEM ⊕ + 10 % FBS can also be used).
-
2.
Remove the cells from the cryotank and thaw them in a small beaker containing autoclaved water warmed to 37 °C in the water bath (It is important that the thawing is done as quickly as possible, and for this reason the beaker containing 37 °C water must be brought to the cryo tank).
A face shield must be worn, as the cryo tube can burst during thawing.
-
3.
Immediately after thawing, carefully transfer the cells to a culture flask, T75 (T25).
Write the data from the cryo tube on the flask.
-
4.
The cells must have their medium changed the day after thawing.
-
5.
After this, the medium is changed every other day (Mon.-Wed.-Fri.), until the cell layer is confluent, after which they are trypsinized.
-
6.
Write in the folder for the cell stock when the cells were thawed and how the cell growth proceeded up until the date of trypsinization.
1.8.2 Passage Nomenclature
Passage = sub-cultivation.
The passage numbers consist of:
Number1-(number2)-number3
Number1
-
Passage Number as the cell line is received—if this number is 1—the cell line is received without a passage number.
( ) + Number2
-
In ( ) is info on freezing. Number2 is the number of trypsinizations before freezing—if there are more numbers in the brackets means that the cell line is proliferated several times.
Number3
-
Number of trypsinizations since thawing.
Example:
Received without passage No.—proliferated by two trypsinizations before freezing: | |
New passage No. at thawing: | 1—(2)—0 |
After first trypsinization: | 1—(2)—1 |
Rights and permissions
Copyright information
© 2016 Controlled Release Society
About this chapter
Cite this chapter
Nielsen, C.U., Brodin, B. (2016). Application of Cell Culture and Tissue Models for Assessing Drug Transport. In: Müllertz, A., Perrie, Y., Rades, T. (eds) Analytical Techniques in the Pharmaceutical Sciences. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-4029-5_26
Download citation
DOI: https://doi.org/10.1007/978-1-4939-4029-5_26
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-4027-1
Online ISBN: 978-1-4939-4029-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)